Hematologic diseases: High risk of Clostridium difficile associated diarrhea

World Journal of Gastroenterology

Volumn 20, Issue 21, 2014, Pages 6602-6607

  Gweon, Tae Geun ^a   Choi, Myung Gyu ^a   Baeg, Myong Ki ^a   Lim, Chul Hyun ^a   Park, Jae Myung ^a   Lee, In Seok ^a   Kim, Sang Woo ^a   Lee, Dong Gun ^a   Park, Yeon Joon ^a   Lee, Jong Wook ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Clinical outcome; Clostridium difficile associated diarrhea; Incidence; Intravenous immunoglobulin; Patients with hematologic disease

Indexed keywords

ACICLOVIR; ADICILLIN; AMINOGLYCOSIDE; BETA LACTAMASE INHIBITOR; CARBAPENEM; CEPHALOSPORIN; COTRIMOXAZOLE; GANCICLOVIR; GLYCOPEPTIDE; IMMUNOGLOBULIN; MACROLIDE; METRONIDAZOLE; PROTON PUMP INHIBITOR; QUINOLONE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; AGE; ARTICLE; BODY MASS; CANCER CHEMOTHERAPY; CLOSTRIDIUM DIFFICILE INFECTION; DISEASE ASSOCIATION; ENZYME IMMUNOASSAY; FEMALE; HEMATOLOGIC DISEASE; HUMAN; INCIDENCE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUTROPENIA; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; RECURRENT DISEASE; RETROSPECTIVE STUDY; AGED; CLOSTRIDIUM INFECTIONS; COMPLICATION; CROSS INFECTION; DIARRHEA; HOSPITALIZATION; MICROBIOLOGY; MULTIVARIATE ANALYSIS; PEPTOCLOSTRIDIUM DIFFICILE; RISK FACTOR; SOUTH KOREA; TERTIARY CARE CENTER;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; DIARRHEA; FEMALE; HEMATOLOGIC DISEASES; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RECURRENCE; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK FACTORS; TERTIARY CARE CENTERS;

EID: 84902096066     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i21.6602     Document Type: Article

References (32)

1. Benson AB, Ajani JA, Catalano RB, Engelking C, Kornblau SM, Martenson JA, McCallum R, Mitchell EP, O'Dorisio TM, Vokes EE, Wadler S. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 2004; 22: 2918-2926 [PMID: 15254061 DOI: 10.1200/ JCO.2004.04.132]
2. Khayr W, Haddad RY, Noor SA. Infections in hematological malignancies. Dis Mon 2012; 58: 239-249 [PMID: 22449371 DOI: 10.1016/j.disamonth.2012.01.001]
3. Freeman J, Bauer MP, Baines SD, Corver J, Fawley WN, Goorhuis B, Kuijper EJ, Wilcox MH. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 2010; 23: 529-549 [PMID: 20610822 DOI: 10.1128/ CMR.00082-09]
4. Willems L, Porcher R, Lafaurie M, Casin I, Robin M, Xhaard A, Andreoli AL, Rodriguez-Otero P, Dhedin N, Socié G, Ribaud P, Peffault de Latour R. Clostridium difficile infection after allogeneic hematopoietic stem cell transplantation: incidence, risk factors, and outcome. Biol Blood Marrow Transplant 2012; 18: 1295-1301 [PMID: 22387347 DOI: 10.1016/ j.bbmt.2012.02.010]
5. Anand A, Glatt AE. Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis 1993; 17: 109-113 [PMID: 8353229]
6. Chopra T, Chandrasekar P, Salimnia H, Heilbrun LK, Smith D, Alangaden GJ. Recent epidemiology of Clostridium difficile infection during hematopoietic stem cell transplantation. Clin Transplant 2011; 25: E82-E87 [PMID: 20973823 DOI: 10.1111/j.1399-0012.2010.01331.x]
7. Alonso CD, Treadway SB, Hanna DB, Huff CA, Neofytos D, Carroll KC, Marr KA. Epidemiology and outcomes of Clostridium difficile infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2012; 54: 1053-1063 [PMID: 22412059 DOI: 10.1093/cid/cir1035]
8. Chong Y, Yakushiji H, Ito Y, Kamimura T. Clinical impact of fluoroquinolone prophylaxis in neutropenic patients with hematological malignancies. Int J Infect Dis 2011; 15: e277-e281 [PMID: 21324723 DOI: 10.1016/j.ijid.2010.12.010]
9. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52: 427-431 [PMID: 21205990 DOI: 10.1093/cid/ciq147]
10. Gorschlüter M, Glasmacher A, Hahn C, Schakowski F, Ziske C, Molitor E, Marklein G, Sauerbruch T, Schmidt-Wolf IG. Clostridium difficile infection in patients with neutropenia. Clin Infect Dis 2001; 33: 786-791 [PMID: 11512083 DOI: 10.1086/322616]
11. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, Mc- Donald LC, Pepin J, Wilcox MH. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31: 431-455 [PMID: 20307191 DOI: 10.1086/651706]
12. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45: 302-307 [PMID: 17599306 DOI: 10.1086/519265]
13. Kim J, Kang JO, Kim H, Seo MR, Choi TY, Pai H, Kuijper EJ, Sanders I, Fawley W. Epidemiology of Clostridium difficile infections in a tertiary-care hospital in Korea. Clin Microbiol Infect 2013; 19: 521-527 [PMID: 22712697 DOI: 10.1111/ j.1469-0691.2012.03910.x]
14. Loo VG, Bourgault AM, Poirier L, Lamothe F, Michaud S, Turgeon N, Toye B, Beaudoin A, Frost EH, Gilca R, Brassard P, Dendukuri N, Béliveau C, Oughton M, Brukner I, Dascal A. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 2011; 365: 1693-1703 [PMID: 22047560 DOI: 10.1056/NEJMoa1012413]
15. O'Connor JR, Johnson S, Gerding DN. Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. Gastroenterology 2009; 136: 1913-1924 [PMID: 19457419 DOI: 10.1053/j.gastro.2009.02.073]
16. Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J, Frost E, McDonald LC. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366: 1079-1084 [PMID: 16182895 DOI: 10.1016/s0140- 6736(05)67420-x]
17. Hu MY, Katchar K, Kyne L, Maroo S, Tummala S, Dreisbach V, Xu H, Leffler DA, Kelly CP. Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. Gastroenterology 2009; 136: 1206-1214 [PMID: 19162027 DOI: 10.1053/j.gastro.2008.12.038]
18. Lo Vecchio A, Zacur GM. Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options. Curr Opin Gastroenterol 2012; 28: 1-9 [PMID: 22134217 DOI: 10.1097/MOG.0b013e32834bc9a9]
19. Viscoli C, Castagnola E. Treatment of febrile neutropenia: what is new? Curr Opin Infect Dis 2002; 15: 377-382 [PMID: 12130933]
20. Lee DG, Kim SH, Kim SY, Kim CJ, Park WB, Song YG, Choi JH. Evidence-based guidelines for empirical therapy of neutropenic fever in Korea. Korean J Intern Med 2011; 26: 220-252 [PMID: 21716917 DOI: 10.3904/kjim.2011.26.2.220]
21. Stevens V, Dumyati G, Fine LS, Fisher SG, van Wijngaarden E. Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis 2011; 53: 42-48 [PMID: 21653301 DOI: 10.1093/cid/cir301]
22. Owens RC, Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 2008; 46 Suppl 1: S19-S31 [PMID: 18177218 DOI: 10.1086/521859]
23. McCollum DL, Rodriguez JM. Detection, treatment, and prevention of Clostridium difficile infection. Clin Gastroenterol Hepatol 2012; 10: 581-592 [PMID: 22433924 DOI: 10.1016/ j.cgh.2012.03.008]
24. Howell MD, Novack V, Grgurich P, Soulliard D, Novack L, Pencina M, Talmor D. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 2010; 170: 784-790 [PMID: 20458086 DOI: 10.1001/archinternmed.2010.89]
25. Kim YG, Graham DY, Jang BI. Proton pump inhibitor use and recurrent Clostridium difficile-associated disease: a casecontrol analysis matched by propensity score. J Clin Gastroenterol 2012; 46: 397-400 [PMID: 22298089 DOI: 10.1097/ MCG.0b013e3182431d78]
26. Blombery P, Prince HM, Worth LJ, Main J, Yang M, Wood EM, Westerman DA. Prophylactic intravenous immunoglobulin during autologous haemopoietic stem cell transplantation for multiple myeloma is not associated with reduced infectious complications. Ann Hematol 2011; 90: 1167-1172 [PMID: 21674144 DOI: 10.1007/s00277-011-1275-3]
27. Raanani P, Gafter-Gvili A, Paul M, Ben-Bassat I, Leibovici L, Shpilberg O. Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation. Cochrane Database Syst Rev 2008; (4): CD006501 [PMID: 18843719 DOI: 10.1002/14651858.CD006501.pub2]
28. Lowy I, Molrine DC, Leav BA, Blair BM, Baxter R, Gerding DN, Nichol G, Thomas WD, Leney M, Sloan S, Hay CA, Ambrosino DM. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010; 362: 197-205 [PMID: 20089970 DOI: 10.1056/NEJMoa0907635]
29. McPherson S, Rees CJ, Ellis R, Soo S, Panter SJ. Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea. Dis Colon Rectum 2006; 49: 640-645 [PMID: 16525744 DOI: 10.1007/ s10350-006-0511-8]
30. Abougergi MS, Kwon JH. Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review. Dig Dis Sci 2011; 56: 19-26 [PMID: 20924675 DOI: 10.1007/ s10620-010-1411-2]
31. Abougergi MS, Broor A, Cui W, Jaar BG. Intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis: an observational study and review of the literature. J Hosp Med 2010; 5: E1-E9 [PMID: 20063275 DOI: 10.1002/jhm.542]
32. Wang MS, Evans CT, Rodriguez T, Gerding DN, Johnson S. Clostridium difficile infection and limitations of markers for severity in patients with hematologic malignancy. Infect Control Hosp Epidemiol 2013; 34: 127-132 [PMID: 23295558 DOI: 10.1086/669081]